Companies /Healthcare
Lantheus Holdings Inc
NASDAQ: LNTH Drug Manufacturers - Specialty & Generic
$100.10
▼ $0.14 (−0.14%) today
Markets closed · 7:35pm ET

Lantheus (LNTH) Q2 2026 Earnings

Reported Aug 6, 2026, 7:45am ET · SEC source
$1.55
Beat +18.90%
EPS · est. $1.30 Adjusted
$388.2M
Beat +6.87%
Revenue · est. $363.2M
−0.3%
Trailing market
LNTH vs S&P since report
4 quarters
Consecutive EPS beats

How Did LNTH Stock React to Q2 2026 Earnings?

% change · around the report
−0.6%0+0.6%Aug 5Aug 13report 7:45am ETearnings+0.9%−0.5%
−0.6%0+0.6%Aug 5Aug 13earnings+0.9%−0.5%
LNTH −0.5%S&P 500 +0.9%
−1%0+1%+2%Aug 5Aug 13report 7:45am ETearnings+2.2%−0.5%
−1%0+1%+2%Aug 5Aug 13earnings+2.2%−0.5%
LNTH −0.5%NASDAQ +2.2%
−0.42%
Day of report
−0.12%
Next session
−0.13%
One week
−0.62%
30 days

S&P 500 over the same 30 days: −0.34%.

Did LNTH Beat Earnings? Q2 2026 Results

Yes. Lantheus reported Q2 2026 earnings of $1.55 a share on Aug 6, 2026, beating the $1.30 consensus estimate by 18.9%. Revenue was $388.2M against a $363.2M estimate.

Lantheus Holdings delivered a strong second-quarter beat on both the top and bottom lines, though the results were quickly overshadowed by a far larger headline: a definitive agreement for Curium US Holdings to acquire the company at $103 per share in cash, plus contingent value rights of up to $12.00 per share tied to commercial milestones, for total per-share consideration of up to $115 and a transaction value of up to approximately $8.00 billion. On the earnings front, adjusted EPS came in at $1.55, clearing the $1.30 consensus by 18.90%, while revenue of $388.18 million beat estimates by 6.87% and grew 2.7% year over year. The revenue mix shifted notably, with Neuraceq contributing $39.62 million after generating no revenue in the prior-year quarter, partially offsetting a 4.1% decline in PYLARIFY to $240.37 million. With the merger pending, Lantheus suspended its full-year 2026 guidance and will not host a quarterly conference call, leaving investors focused squarely on deal completion rather than the operational outlook.

Key Takeaways
  • DEFINITY sales grew 5.2% year-over-year to $88.3 million
  • Neuraceq contributed $39.6 million in revenue, a new revenue stream not present in Q2 2025
  • Strategic partnerships and other revenue increased 71.9%
  • PYLARIFY sales declined 4.1% to $240.4 million
  • SPECT revenue dropped to zero from $31.9 million in the prior year

What Is Lantheus's Outlook?

Lantheus suspended its previously issued full year 2026 financial guidance in connection with the pending merger with Curium. No updated forward guidance was provided.

LNTH YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$200.0M$400.0M$378.0M$388.2MRevenue$241.0M$241.9MGross Profit$88.0M$100.2MOperating Income$78.8M$75.0MNet Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income
LNTH income statement, Q2 2026 versus Q2 2025
Metric Q2 2026 Q2 2025 Year over year
Revenue $388.2M $378.0M +2.7%
Gross Profit $241.9M $241.0M +0.4%
Operating Income $100.2M $88.0M +13.9%
Net Income $75.0M $78.8M −4.7%

LNTH Revenue by Segment

PYLARIFY$240.4M−4.1%
DEFINITY$88.3M+5.2%
Neuraceq$39.6M+100.0%
TechneLite
Strategic partnerships and other revenue
Strategic partnerships and other$19.9M+71.9%
Other precision diagnostics

When Does Lantheus Report Next?

Expected report date

Figures from SEC filings and company reports. Not investment advice.